# Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS

> **NCT01911377** · PHASE2 · TERMINATED · sponsor: **University of Manitoba** · enrollment: 12 (actual)

## Conditions studied

- Neuropathic Pain
- Allodynia

## Interventions

- **DRUG:** Botulinum Toxin Type A
- **DRUG:** Normal Saline for Injection

## Key facts

- **NCT ID:** NCT01911377
- **Lead sponsor:** University of Manitoba
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** 12 SCI volunteers completed the study. As the data analysis was negative, the decision was made not to proceed with MS recruitment.
- **Last updated:** 2015-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01911377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01911377, "Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01911377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*